Floatz logo

anv419

Metastatic Melanoma

Anaveon AGPhase 1/2Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

103 Active assets in the Metastatic Melanoma cohort.

Asset / SponsorPhaseRating
Cediranib
M.D. Anderson Cancer Center
Phase 2BBB
DACARBAZINE
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Ifa
Craig L Slingluff, Jr
Phase 2BB
Nivolumab
Bristol-Myers Squibb
Phase 4BB
Therapeutic Autologous Lymphocytes
Fred Hutchinson Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

anv419 is also rated in:

Adult DiseaseDormant
B
Indicative ·
58 / 100
View asset →
melanomaDormant
CCC
Indicative ·
55 / 100
View asset →
cancerDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →